Drug metabolism

Foye's Principles of Medicinal Chemistry: Seventh Edition

Volumn , Issue , 2013, Pages 106-190

  Williams, David A ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971201043     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (109)

1. Williams RT. Detoxication Mechanisms, 2nd Ed. New York: John Wiley and Sons, 1959.
2. Anders M, ed. Bioactivation of Foreign Compounds. New York: Academic Press, 1985.
3. Jakoby W, ed. Enzymatic Basis of Detoxication, vols I and II. New York: Academic Press, 1980.
4. Jakoby W, Bend JR, Caldwell J, eds. Metabolic Basis of Detoxication- Metabolism of Functional Groups. New York: Academic Press, 1982.
5. Mulder GJ, ed. Conjugation Reactions in Drug Metabolism: An Integrated Approach. London: Taylor and Francis, 1990.
6. Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 2nd Ed. New York: Plenum Press, 1995.
7. Testa B, Krämer SD. The Biochemistry of Drug Metabolism. Volume 1: Principles, Redox Reactions, Hydrolyses and Volume 2: Conjugations, Consequences of Metabolism, Influencing Factors. New York: Wiley-VCH, 2005.
8. Rodrigues AD. Drug-Drug Interactions, 2nd Ed (Drugs and the Pharmaceutical Sciences Volume 179). New York: Informa Healthcare, 2008.
9. Pearson PG, Wienkers LC. Handbook of Drug Metabolism, 2nd Ed (Drugs and the Pharmaceutical Sciences Volume 186). New York: Informa Healthcare, 2008.
10. Murphy MP. Pharmacogenomics: a new paradigm for drug development. Drug Discov World 2000;1:23-32.
11. Wilkinson GR, Schenker S. Drug disposition and liver disease. Drug Metab Rev 1975;4:139-175.
12. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991;21:42-69.
13. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 1999;37:399-443.
14. Groves JT. Models and mechanisms of cytochrome P450. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:1-44.
15. Nielson KA, Moller BL. Cytochrome P450 in plants. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:553.
16. Nebert DW, Nelson DR, Coon MJ, et al. The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 1991;10:1-14.
17. Gonzalez FJ, Gelboin HV. Human cytochromes P450: evolution and cDNAdirected expression. Environ Health Perspect 1992;98:810-885.
18. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions substrates inducers and inhibitors. Drug Metab 1997;29:413-580.
19. Guengerich FP. Enzymatic oxidation of xenobiotic chemicals. Crit Rev Biochem Mol Biol 1990;25:97-153.
20. Meunier B, de Visser SP, Shaik S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem Rev 2004;104:3947-3980.
21. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:377-530.
22. Traber PG, McDonnell WM, Wang R. Expression and regulation of cytochrome P450I genes (CYP1A1 and CYP1A2) in the rat alimentary tract. Biochim Biophys Acta 1992;1171:167-175.
23. Roy D, Bernhardt A, Strobel H, et al. Catalysis of the oxidation of steroid and stilbene estrogens to estrogen quinone metabolites by the ß-naphthoflavone-inducible cytochrome CYP1A family. Arch Biochem Biophys 1992;296:450-456.
24. Koop DR. Oxidative and reductive metabolism of cytochrome P4502E1. FASEB J 1992;6:724-730.
25. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 1993;23:1-20.
26. White RE, Coon MJ. Oxygen activation by cytochrome P450. Ann Rev Biochem 1980;49:315-356.
27. Makris TM, Denisov L, Schlichting L, et al. Activation of molecular oxygen by cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:149-182.
28. Groves JT. Key elements of the chemistry of cytochrome P450. The oxygen rebound mechanism. J Chem Educ 1985;62:928-931.
29. Ortiz de Montellano PR, DeVoss JJ. Substrate oxidation by cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:193-198.
30. Guengerich FP, MacDonald TL. Mechanisms of cytochrome P450 catalysis. FASEB J 1990;4:2453-2459.
31. Ortiz de Montellano PR. Cytochrome P-450 catalysis: radical intermediates and dehydrogenation reactions. Trends Pharmacol Sci 1989;10:354-359.
32. Correia MA, Ortiz de Montellano PR. Inhibition of cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:247-322.
33. Ortiz de Montellano PR. Alkenes and alkynes. In: Anders M, ed. Bioactivation of Foreign Compounds. New York: Academic Press, 1985:121-155.
34. Williams SN, Dunkan E, Bradfield CA. Induction of cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:323-346.
35. Okey AB. Enzyme induction in the cytochrome P450 system. Pharmacol Ther 1990;45:241-298.
36. Barry M, Feely J. Enzyme induction and inhibition. Pharmacol Ther 1992;48:71-94.
37. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992;54:17-61.
38. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993;57:237-257.
39. Conney AH, Pantuck EJ, Kuntzman R, et al. Nutrition and chemical biotransformations in man. Clin Pharmacol Ther 1977;22:707-711.
40. Murray M, Reidy GF. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 1990;42:85-101.
41. Murray M. P450 enzymes. Clin Pharmacokinet 1992;23:132-146.
42. Ballie TA. Metabolism of valproate to hepatotoxic intermediates. Pharm Weekbl Sci 1992;14:122-125.
43. Thummel KE, Kharasch ED, Podoll T, et al. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 1993;21:350-356.
44. Elliot RH, Strunun L. Hepatotoxicity of volatile anesthetics. Br J Anaesth 1993;70:339-348.
45. Zeigler DM. Flavin-containing monooxygenases. Drug Metab Rev 1988;19:1-32.
46. Zeigler DM. Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Trends Pharmacol Sci 1990;11:321-324.
47. Singer TP, Ramsay RR. Mechanism of neurotoxicity of MPTP. FEBS Lett 1990;274:1-8.
48. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005;106:357-387.
49. Cashman JR, Wang Z, Yang L, et al. Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult liver microsomes. Drug Metab Dispos 1993;21:492-501.
50. Hollenberg PF. Mechanism of cytochrome P450 and peroxide-catalyzed xenobiotic metabolism. FASEB J 1992;6:686-694.
51. Marnett LJ, Kenned TY. Comparison of the peroxidase activity of hemeproteins and cytochrome P450. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure Mechanism and Biochemistry, 3rd Ed. New York: Plenum Press, 2005:49-80.
52. Hille R. Molybdenum enzymes. Essays Biochem 1999;34:125-137.
53. Kitamura S, Sugihara K, Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 2006;21:83-98.
54. Lang D, Kalgutkar AS. Non-P450 mediated oxidative metabolism of xenobiotics. In: Lee JS, Obach RS, Fisher MB, eds. Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development. New York: FontisMedia-Marcel Dekker, 2003:483-539.
55. Costa LG, Li WF, Richter RJ, et al. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 1999;119-120:429-439.
56. Mulder GJ, ed. Conjugation Reactions in Drug Metabolism: An Integrated Approach. New York: Taylor and Francis, 1990.
57. Jansen PLM, Mulder PJ, Burchell B, et al. New developments in glucuronidation research: report of a workshop on "glucuronidation, its role in health and disease." Hepatology 1992;15:532-544.
58. Burchell B, Mcgurk K, Brierly CH, et al. UDP-glucuronosyltransferases. In: Guengerich FP, ed. Comprehensive Toxicology, Vol 3. New York: Pergamon- Elsevier Science, 1997:449-473.
59. Spahn-Langguth H, Benet LZ. Acylglucuronides revisited: is the glucuronidation process a toxification as well as a detoxication mechanism. Drug Metab Rev 1992;24:5-48.
60. Mulder GJ. Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception. Trends Pharmacol Sci 1992;13:302-304.
61. Falani CN. Enzymology of human cytosolic sulfotransferases. FASEB J 1997;11:206-216.
62. Lindsay J, Wang LL, Li Y, et al. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008;9:99-105.
63. Caldwell J, Hutt AJ, Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological activity. Biochem Pharmacol 1988;37:105-115.
64. Tracy TS, Wirthwein DP, Hall SD. Metabolic inversion of R-ibuprofen. Drug Metab Dispos 1993;21:114-119.
65. Nelson SD. Arylamines and arylamide: oxidation mechanisms. In: Anders M, ed. Bioactivation of Foreign Compounds. New York: Academic Press, 1985:349-375.
66. Ahmed AE. Nitriles. In: Anders M, ed. Bioactivation of Foreign Compounds. New York: Academic Press, 1985:485-489.
67. Dobrinska MR. Enterohepatic circulation of drugs. J Clin Pharmacol 1989;29:577-580.
68. Ilett KF, Tee LBG, Reeves PT, et al. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990;46:67-93.
69. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985;37:133-145.
70. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990;19:359-389.
71. Woodhouse K, Wynne HA. Age-related changes in hepatic function: implications for drug therapy. Drugs Aging 1992;2:243-246.
72. Smit JW, Huisman MT, van Tellingen O, et al. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999;104:1441-1447.
73. Ingelmann-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-349.
74. Di YM, Chow VD, Yang LP, et al. Structure, function, regulation and polymorphism of human cytochrome CYP2A6. Curr Drug Metab 2009;10:754-780.
75. Mo SL, Liu YH, Duan W, et al. Substrate specificity, regulation, and polymorphism of human cytochrome CYP2B6. Curr Drug Metab 2009;10:730-753.
76. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome CYP2C9 and the functional relevance. Toxicology 2010;278:165-188.
77. Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450. Crit Rev Toxicol 1991;21:407-422.
78. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000;75:933-942.
79. Yu Dk. The contribution of P-glycoprotein to the pharmacokinetics of drug- drug interactions. J Clin Pharmacol 1999;39:1203-1211.
80. Silverman JA. Multidrug resistance transporters. Pharm Biotechnol 1999;12:353-386.
81. Oesch F. Metabolic transformation of clinically used drugs to epoxides: new perspectives in drug-drug interactions. Biochem Pharmacol 1976;25:1935-1937.
82. Ohnishi A, Matsuo H, Yamada S, et al. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome CYP3A4. Br J Pharmacol 2000;130:1369-1377.
83. Watkins PB. Role of cytochrome P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990;10:235-250.
84. Roth RA, Vinegar A. Action by the lungs on circulating xenobiotic agents, with a case study of physiologically based pharmacokinetic modeling of benzo[a]pyrene disposition. Pharmacol Ther 1990;48:143-155.
85. Reed CJ. Drug metabolism in the nasal cavity. Drug Metab Rev 1993;25:173-205.
86. Sarkar MA. Drug metabolism in the nasal mucosa. Pharmacol Res 1992;9:1-8.
87. Testa B, Jenner P, eds. Drug Metabolism: Chemical and Biological Aspects. New York: Marcel Dekker, 1976.
88. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485.
89. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739.
90. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA 2006;296:87-93.
91. Park BK, Kitteringham NR, Maggs JL, et al. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005;45:177-202.
92. Williams DP, Kitteringham NR, Naisbitt DJ, et al. Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr Drug Metab 2002;3:351-366.
93. Kalgutkar AS, Gardner I, Obach RS, et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225.
94. Myers TG, Dietz EC, Anderson N, et al. A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3'-hydroxyacetanilide. Chem Res Toxicol 1995;8:403-413.
95. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006;8:E48-E54.
96. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002;3:367-377.
97. Miller EC, Miller JA. Mechanisms of chemical carcinogenesis. Cancer 1981;47:1055-1064.
98. Gillette JR. The problem of chemically reactive metabolites. Drug Metab Rev 1982;13:941-961.
99. Reed DJ. Cellular defense mechanisms against reactive metabolites. In: Anders M, ed. Bioactivation of Foreign Compounds. New York: Academic Press, 1985:71-108.
100. Nelson SD, et al. Role of metabolic activation in chemical-induced tissue injury. In: Jerina DM, ed. Drug Metabolism Concepts. ACS Symposium Series 44. Washington, DC: American Chemical Society, 1977:155-185.
101. Uetrecht J. Bioactivation. In: Lee JS, Obach RS, Fisher M, eds. Drug- Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development. Weimar, TX: Culinary and Hospitality Industry Publications Services, 2003:87-145.
102. Boelsterli UA. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein- reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab 2002;3:439-450.
103. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome CYP3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304.
104. Dressor GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome CYP3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
105. Murray M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab 2000;1:67-84.
106. Bailey DG, Dresser GK, Kreeft JH, et al. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000;68:468-477.
107. Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 2000;22:131-136.
108. Johnson BM, Van Breemen RB. In vitro formation of quinoid metabolites of the dietary supplement cimicifuga racemosa (black cohosh). Chem Res Toxicol 2003;16:838-846.
109. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-2063.